Form 4: Soleno Therapeutics Merger: Kristen Yen Transactions

Kristen Yen, SVP Global Clinical Operations at Soleno Therapeutics, reports transactions related to the company's merger with Neocrine Biosciences.

Summary

• Kristen Yen, SVP Global Clinical Operations and Patient Advocacy at Soleno Therapeutics, Inc., has reported transactions on May 18, 2026, related to the company's merger.
• The merger involved Soleno Therapeutics, Inc. (the 'Company'), Neocrine Biosciences, Inc. ('Parent'), and Sigma Merger Sub, Inc. ('Merger Sub').
• In connection with the merger, each outstanding share of Soleno Therapeutics' Common Stock was converted into the right to receive $53.00 in cash.
• Vested and unvested Restricted Stock Units (RSUs) were also cancelled and converted into the right to receive $53.00 in cash per unit.
• Employee stock options were cancelled in exchange for a cash payment equal to the difference between the merger consideration ($53.00) and the option's exercise price, multiplied by the number of shares covered by the option.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive for the reporting person, as it details the realization of value through a merger. For other stakeholders, the impact depends on their individual positions and expectations regarding the company's future.

Positives

• The merger provides a cash payout of $53.00 per share for common stock holders, representing a realization of value.
• All outstanding vested and unvested RSUs are converted into cash, providing immediate liquidity for RSU holders.
• Employee stock options are being cashed out, with the payout reflecting the intrinsic value (spread between exercise price and merger consideration).

Negatives

• Common stockholders, RSU holders, and option holders will receive cash, indicating the end of their equity participation in the combined entity.
• The filing details the cancellation of equity awards, which may be viewed negatively by employees who expected continued equity participation.

Risks

• The primary risk is the completion of the merger as outlined, although the Form 4 indicates the transaction has occurred.
• Potential for disputes or disagreements regarding the valuation of stock options or the calculation of cash payouts.

Future Outlook

The filing pertains to a completed merger, indicating that Soleno Therapeutics, Inc. will cease to exist as an independent publicly traded entity. Future outlook is now tied to the performance of the acquiring entity, Neocrine Biosciences, Inc.

Management Comments

• The filing indicates that Kristen Yen holds the title of SVP Global Clinical Operations and Patient Advocacy.
• The transactions are executed under a Rule 10b5-1(c) contract, instruction, or written plan, intended to satisfy affirmative defense conditions.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant event in the biotechnology sector: a merger. Such transactions often involve the acquisition of smaller, potentially innovative companies by larger entities, leading to cash payouts for existing shareholders and option holders, and a transition to a private or consolidated public entity.

Comparison to Industry Standards

• The merger consideration of $53.00 per share is a specific valuation determined by the parties involved in the transaction. Without knowing the pre-announcement trading price or recent financial performance of Soleno Therapeutics, it is difficult to compare this valuation to industry standards.
• The treatment of stock options, where the spread between the exercise price and the merger consideration is paid in cash, is a standard practice in merger and acquisition transactions within the pharmaceutical and biotechnology industries.

Stakeholder Impact

• Shareholders: Receive $53.00 in cash per share, realizing their investment.
• Employees (Option Holders): Receive cash payments based on the intrinsic value of their options, ending their equity stake.
• Employees (RSU Holders): Receive $53.00 in cash per RSU, realizing the value of their awards.
• Creditors: The impact on creditors is not directly detailed, but the acquisition by a new entity may alter debt structures or obligations.

Next Steps

• Shareholders, RSU holders, and option holders will receive their respective cash payouts as per the merger agreement.
• Soleno Therapeutics, Inc. will become a wholly owned subsidiary of Neocrine Biosciences, Inc.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Neocrine Biosciences, Kristen Yen, Form 4, SEC Filing, Stock Options, RSUs, Beneficial Ownership, Insider Transactions